UA86582C2 - Способ лечения хореи гентингтона ейкозапентеновой кислотой - Google Patents

Способ лечения хореи гентингтона ейкозапентеновой кислотой

Info

Publication number
UA86582C2
UA86582C2 UAA200505201A UA2005005201A UA86582C2 UA 86582 C2 UA86582 C2 UA 86582C2 UA A200505201 A UAA200505201 A UA A200505201A UA 2005005201 A UA2005005201 A UA 2005005201A UA 86582 C2 UA86582 C2 UA 86582C2
Authority
UA
Ukraine
Prior art keywords
huntington
treatment
eicosapentaenoic acid
chorea
ера
Prior art date
Application number
UAA200505201A
Other languages
English (en)
Ukrainian (uk)
Inventor
Дейвид Фредерик Хорробин
Original Assignee
Эймерин Ньюросаенс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эймерин Ньюросаенс Лимитед filed Critical Эймерин Ньюросаенс Лимитед
Publication of UA86582C2 publication Critical patent/UA86582C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Заявленное изобретение относится к способу идентификации пациентов, которые, возможно, будут реагировать на лечение хореи Гентингтона ейкозапентеновой кислотой (ЕРА), путем анализа гена белка Гентингтона.
UAA200505201A 2002-12-02 2003-11-26 Способ лечения хореи гентингтона ейкозапентеновой кислотой UA86582C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0228079.0A GB0228079D0 (en) 2002-12-02 2002-12-02 Huntington's Disease

Publications (1)

Publication Number Publication Date
UA86582C2 true UA86582C2 (ru) 2009-05-12

Family

ID=9948921

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200505201A UA86582C2 (ru) 2002-12-02 2003-11-26 Способ лечения хореи гентингтона ейкозапентеновой кислотой

Country Status (28)

Country Link
US (2) US20070148643A1 (ru)
EP (1) EP1567667B1 (ru)
JP (1) JP2006507833A (ru)
KR (1) KR20050086895A (ru)
CN (1) CN1717497A (ru)
AT (1) ATE411399T1 (ru)
AU (1) AU2003285519A1 (ru)
BR (1) BR0316969A (ru)
CA (1) CA2506727A1 (ru)
CY (1) CY1108730T1 (ru)
DE (1) DE60324180D1 (ru)
DK (1) DK1567667T3 (ru)
ES (1) ES2315543T3 (ru)
GB (1) GB0228079D0 (ru)
HR (1) HRP20050493A2 (ru)
IS (1) IS7842A (ru)
MX (1) MXPA05005908A (ru)
MY (1) MY138759A (ru)
NO (1) NO20052955L (ru)
NZ (1) NZ539989A (ru)
PL (1) PL376101A1 (ru)
PT (1) PT1567667E (ru)
RU (1) RU2332209C2 (ru)
SI (1) SI1567667T1 (ru)
TW (1) TWI306120B (ru)
UA (1) UA86582C2 (ru)
WO (1) WO2004050913A1 (ru)
ZA (1) ZA200504003B (ru)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1713463A4 (en) * 2004-01-19 2009-03-18 Martek Biosciences Corp REELIN DYSFUNCTION OR DICTION AND ASSOCIATED TECHNIQUES
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
EP1857548A1 (en) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
JP6047270B2 (ja) 2006-08-11 2016-12-21 バイオマリン テクノロジーズ ベー．フェー． Ｄｎａリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段
CN103212085A (zh) 2007-07-12 2013-07-24 普罗森那技术公司 用于使化合物靶向多种选定器官或组织的分子
CA2693742A1 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
EP2203173B1 (en) 2007-10-26 2015-12-23 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
WO2009099326A1 (en) 2008-02-08 2009-08-13 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
EP4137128A1 (en) 2008-09-02 2023-02-22 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same
ES2768091T3 (es) 2009-02-10 2020-06-19 Amarin Pharmaceuticals Ie Ltd Uso del éster etílico del ácido eicosapentaenoico para tratar la hipertrigliceridemia
EP2421971B1 (en) 2009-04-24 2016-07-06 BioMarin Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
NZ720946A (en) 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX350088B (es) 2009-04-29 2017-08-25 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
CN108096209A (zh) 2009-06-15 2018-06-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
EP2516647B1 (en) 2009-12-24 2016-12-14 BioMarin Technologies B.V. Molecule for treating an inflammatory disorder
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ712068A (en) 2010-11-29 2017-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
CN118581086A (zh) 2012-01-27 2024-09-03 比奥马林技术公司 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
CA3067012C (en) 2012-06-29 2021-10-05 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA51766A (fr) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
BR112022009189A2 (pt) 2019-11-12 2022-07-26 Amarin Pharmaceuticals Ie Ltd Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6A (en) * 1836-08-10 Thomas Blanchard Machine for forming end pieces of plank blocks for ships
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
CA2116280A1 (en) * 1993-03-05 1994-09-06 Marcy E. Macdonald Huntingtin dna, protein and uses thereof
CA2094169A1 (en) * 1993-04-16 1994-10-17 Rick E. Preddie Agents for the prevention and cure of huntington disease in humans: cdna, precursor polypeptide hormone and active hormone reconstructed from the antisense strand of the huntingtondisease gene, "huntingtin"
CA2216057A1 (en) * 1997-09-19 1999-03-19 Ridha Joober Polymorphic cag repeat-containing gene, diagnosis of psychiatric diseases and therapeutic uses thereof
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
JP2003510349A (ja) * 1999-10-07 2003-03-18 ノヴァ−ニューロン インコーポレーテッド 線条体機能に必要な遺伝子、その使用、およびそれを調節するための化合物

Also Published As

Publication number Publication date
RU2332209C2 (ru) 2008-08-27
BR0316969A (pt) 2005-10-25
EP1567667A1 (en) 2005-08-31
SI1567667T1 (sl) 2009-04-30
NO20052955L (no) 2005-06-16
TWI306120B (en) 2009-02-11
RU2005115536A (ru) 2006-01-27
CN1717497A (zh) 2006-01-04
CA2506727A1 (en) 2004-06-17
GB0228079D0 (en) 2003-01-08
JP2006507833A (ja) 2006-03-09
ZA200504003B (en) 2007-01-31
US20070148643A1 (en) 2007-06-28
TW200418993A (en) 2004-10-01
IS7842A (is) 2005-05-12
ATE411399T1 (de) 2008-10-15
AU2003285519A1 (en) 2004-06-23
MXPA05005908A (es) 2005-12-12
CY1108730T1 (el) 2014-04-09
WO2004050913A1 (en) 2004-06-17
US20090270504A1 (en) 2009-10-29
ES2315543T3 (es) 2009-04-01
NZ539989A (en) 2006-11-30
MY138759A (en) 2009-07-31
KR20050086895A (ko) 2005-08-30
PT1567667E (pt) 2008-11-04
HK1081598A1 (en) 2006-05-19
HRP20050493A2 (en) 2005-10-31
DK1567667T3 (da) 2009-01-12
EP1567667B1 (en) 2008-10-15
PL376101A1 (en) 2005-12-12
DE60324180D1 (de) 2008-11-27

Similar Documents

Publication Publication Date Title
PT1567667E (pt) Tratamento da doença de huntington com epa
WO2005008591A3 (en) System and method for endoscopic path planning
WO2002096363A3 (en) Method for treating fibrotic diseases or other indications
PT1562941E (pt) Trans-9,10-desidroepotilona c e d, seus análogos e métodos de fabrico dos mesmos
ATE296839T1 (de) Antikörper zur krebsbehandlung und -diagnose
AU2003233451A1 (en) Targets, methods, and reagents for diagnosis and treatment of schizophrenia
AU2003243096A1 (en) NOVEL PURINE- OR PYRROLOL(2,3-d)PYRIMIDINE-2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY
AU2003274869A1 (en) A method and an apparatus for determining the efficiency of dialysis
AU2002317557A1 (en) Afinity biosensor for monitoring of biological process
WO2004071572A3 (en) Gene expression markers for response to egfr inhibitor drugs
WO2004007743A3 (en) Use of cpg nucleic acids in prion-disease
WO2005099716A3 (en) Method for analyzing the biological age of a subject
WO2000018954A3 (en) Use of pex in the treatment of metabolic bone diseases
AU2003237709A1 (en) Thermosensitive polymer carriers having a modifiable physical structure for biochemical analysis, diagnosis, and therapy
BR9714523A (pt) Tratamento de nefrite de lúpus com compostos anti-cd40l
AU2003293141A1 (en) Methods for identifying risk of breast cancer and treatments thereof
WO1999012951A8 (en) Uses of nicotinamide adenine dinucleotide and its analogs for treatment of malignant and infectious diseases
AU2001245319A1 (en) Methods of treating diseases with activated protein c
WO2006041409A8 (en) Medical solution, method for producing and use thereof
MY139578A (en) Method for separating poly-3-hydroxyalkanoic acid
EA200000740A1 (ru) Способ лечения заболевания хронической закупорки легочных путей
ZA200502307B (en) Method for treating patients with massive blood loss
WO2000011215A3 (en) Method for diagnostic screening
WO2004018504A3 (de) Immunmarker zur diagnostik und therapie im zusammenhang mit transplantat-reaktionen
WO2003107545A3 (en) Methods for identifying compounds for treating disease states